Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cost benefit AND influenza AND vaccination AND vaccines:

Search results

Items: 1 to 20 of 387

1.

Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia.

Lara C, De Graeve D, Franco F.

Value Health Reg Issues. 2018 Apr 4;17:21-31. doi: 10.1016/j.vhri.2018.01.001. [Epub ahead of print]

PMID:
29626706
2.

[Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain].

Pérez-Rubio A, Eiros JM.

Rev Esp Quimioter. 2018 Feb;31(1):43-52. Epub 2017 Jan 18. Spanish.

3.

Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.

Van Bellinghen LA, Marijam A, Tannus Branco de Araujo G, Gomez J, Van Vlaenderen I.

Braz J Infect Dis. 2018 Jan - Feb;22(1):1-10. doi: 10.1016/j.bjid.2017.11.004. Epub 2018 Jan 18.

4.

Conserved peptides enhance immune efficiency of inactive vaccines against emerging avian influenza viruses in chicken.

Xiao J, Zhang L, Wang Z, Xiang W, Lu P, Zhao Y, Han M, Ma A, Qi P, Wang M, Gao GF, Liu WJ.

Sci China Life Sci. 2017 Dec;60(12):1340-1347. doi: 10.1007/s11427-017-9153-2. Epub 2017 Sep 8.

PMID:
29230639
5.

fluEvidenceSynthesis: An R package for evidence synthesis based analysis of epidemiological outbreaks.

van Leeuwen E, Klepac P, Thorrington D, Pebody R, Baguelin M.

PLoS Comput Biol. 2017 Nov 20;13(11):e1005838. doi: 10.1371/journal.pcbi.1005838. eCollection 2017 Nov.

6.

School-Based Influenza Vaccination: Health and Economic Impact of Maine's 2009 Influenza Vaccination Program.

Basurto-Dávila R, Meltzer MI, Mills DA, Beeler Asay GR, Cho BH, Graitcer SB, Dube NL, Thompson MG, Patel SA, Peasah SK, Ferdinands JM, Gargiullo P, Messonnier M, Shay DK.

Health Serv Res. 2017 Dec;52 Suppl 2:2307-2330. doi: 10.1111/1475-6773.12786.

PMID:
29130266
7.

Both hemispheric influenza vaccine recommendations would have missed near half of the circulating viruses in Madagascar.

Guillebaud J, Héraud JM, Razanajatovo NH, Livinski AA, Alonso WJ.

Influenza Other Respir Viruses. 2017 Nov;11(6):473-478. doi: 10.1111/irv.12517.

8.

Variation in loss of immunity shapes influenza epidemics and the impact of vaccination.

Woolthuis RG, Wallinga J, van Boven M.

BMC Infect Dis. 2017 Sep 19;17(1):632. doi: 10.1186/s12879-017-2716-y.

9.

Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.

Raviotta JM, Smith KJ, DePasse J, Brown ST, Shim E, Nowalk MP, Wateska A, France GS, Zimmerman RK.

Vaccine. 2017 Oct 9;35(42):5708-5713. doi: 10.1016/j.vaccine.2017.07.069. Epub 2017 Sep 7.

PMID:
28890196
10.

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England.

Thorrington D, van Leeuwen E, Ramsay M, Pebody R, Baguelin M.

BMC Med. 2017 Sep 8;15(1):166. doi: 10.1186/s12916-017-0932-3.

11.

Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ≤60 months of age.

Kittikraisak W, Suntarattiwong P, Ditsungnoen D, Pallas SE, Abimbola TO, Klungthong C, Fernandez S, Srisarang S, Chotpitayasunondh T, Dawood FS, Olsen SJ, Lindblade KA.

PLoS One. 2017 Aug 24;12(8):e0183391. doi: 10.1371/journal.pone.0183391. eCollection 2017.

12.

A systematic review of the health economic consequences of quadrivalent influenza vaccination.

de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, Pitman R, Wilschut JC, Postma MJ.

Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):249-265. doi: 10.1080/14737167.2017.1343145. Epub 2017 Jun 28. Review.

PMID:
28613092
13.

Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study.

DePasse JV, Nowalk MP, Smith KJ, Raviotta JM, Shim E, Zimmerman RK, Brown ST.

Vaccine. 2017 Jul 13;35(32):3974-3981. doi: 10.1016/j.vaccine.2017.05.093. Epub 2017 Jun 9.

PMID:
28606814
14.

A systematic review of economic evaluations of seasonal influenza vaccination for the elderly population in the European Union.

Shields GE, Elvidge J, Davies LM.

BMJ Open. 2017 Jun 10;7(6):e014847. doi: 10.1136/bmjopen-2016-014847. Review.

15.

Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions.

Pasquini-Descomps H, Brender N, Maradan D.

Value Health. 2017 Jun;20(6):819-827. doi: 10.1016/j.jval.2016.05.005. Epub 2016 Jun 29. Review.

PMID:
28577700
16.

Sozialer und ökonomischer Nutzen der Impfung gegen Influenza.

Blank PR, Szucs TD.

Praxis (Bern 1994). 2017;106(11):589-593. doi: 10.1024/1661-8157/a002693. Review. German. No abstract available.

PMID:
28537112
17.

Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review.

Wong CKH, Liao Q, Guo VYW, Xin Y, Lam CLK.

Vaccine. 2017 May 31;35(24):3153-3161. doi: 10.1016/j.vaccine.2017.04.050. Epub 2017 May 2. Review.

18.

Cost effectiveness of influenza vaccination in patients with acute coronary syndrome in Korea.

Suh J, Kim B, Yang Y, Suh DC, Kim E.

Vaccine. 2017 May 15;35(21):2811-2817. doi: 10.1016/j.vaccine.2017.04.016. Epub 2017 Apr 17.

PMID:
28427844
19.

Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study.

DePasse JV, Smith KJ, Raviotta JM, Shim E, Nowalk MP, Zimmerman RK, Brown ST.

Am J Epidemiol. 2017 May 1;185(9):822-831. doi: 10.1093/aje/kww229.

20.

The Cost of Cost-Sharing: The Impact of Medicaid Benefit Design on Influenza Vaccination Uptake.

Stoecker C, Stewart AM, Lindley MC.

Vaccines (Basel). 2017 Mar 6;5(1). pii: E8. doi: 10.3390/vaccines5010008.

Supplemental Content

Loading ...
Support Center